Literature DB >> 11897680

The ubiquitin-proteasome pathway regulates the availability of the GH receptor.

Peter van Kerkhof1, Mirjam Smeets, Ger J Strous.   

Abstract

GH promotes not only longitudinal growth in children but is active throughout life in protein, fat, and carbohydrate metabolism. The multiple actions of GH start when GH binds to the cell surface-expressed GH receptor. Effectiveness of the hormone depends both on its presence in the circulation and the availability of receptors at the cell surface of target cells. In this study, we examined the role of the ubiquitin-proteasome pathway in regulating GH receptor availability. We show that receptor turnover is rapid, and almost 3-fold prolonged in the internalization-deficient mutant GH receptor (F327A). Using a monovalent GH antagonist, B2036, we could quantify the internalization of the nonactivated receptor. By comparing internalization of the receptor with shedding of the GH-binding protein, we show that in Chinese hamster lung cell lines, internalization followed by lysosomal degradation is the major pathway for receptor degradation and that the ubiquitin-proteasome pathway controls this process. Inhibition of endocytosis resulted in a 200% increase in receptor availability at the cell surface at steady state.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897680     DOI: 10.1210/endo.143.4.8755

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Ubc13 and COOH terminus of Hsp70-interacting protein (CHIP) are required for growth hormone receptor endocytosis.

Authors:  Johan A Slotman; Ana C da Silva Almeida; Gerco C Hassink; Robert H A van de Ven; Peter van Kerkhof; Hendrik J Kuiken; Ger J Strous
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

2.  Growth hormone-induced JAK2 signaling and GH receptor down-regulation: role of GH receptor intracellular domain tyrosine residues.

Authors:  Luqin Deng; Jing Jiang; Stuart J Frank
Journal:  Endocrinology       Date:  2012-03-13       Impact factor: 4.736

3.  Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase.

Authors:  Alex N Bullock; Judit E Debreczeni; Aled M Edwards; Michael Sundström; Stefan Knapp
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-04       Impact factor: 11.205

4.  Multimeric growth hormone receptor complexes serve as signaling platforms.

Authors:  Magdalena Sedek; Lieke M van der Velden; Ger J Strous
Journal:  J Biol Chem       Date:  2013-11-26       Impact factor: 5.157

5.  The growth hormone receptor interacts with its sheddase, the tumour necrosis factor-alpha-converting enzyme (TACE).

Authors:  Julia A Schantl; Marcel Roza; Peter Van Kerkhof; Ger J Strous
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

6.  LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice.

Authors:  Thierry Touvier; Françoise Conte-Auriol; Olivier Briand; Céline Cudejko; Réjane Paumelle; Sandrine Caron; Eric Baugé; Yves Rouillé; Jean-Pierre Salles; Bart Staels; Bernard Bailleul
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

7.  Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis.

Authors:  Jürgen Gent; Peter van Kerkhof; Marcel Roza; Guojun Bu; Ger J Strous
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

Review 8.  Modulation of growth hormone receptor abundance and function: roles for the ubiquitin-proteasome system.

Authors:  Stuart J Frank; Serge Y Fuchs
Journal:  Biochim Biophys Acta       Date:  2008-06-09

Review 9.  Growth Hormone Receptor Regulation in Cancer and Chronic Diseases.

Authors:  Ger J Strous; Ana Da Silva Almeida; Joyce Putters; Julia Schantl; Magdalena Sedek; Johan A Slotman; Tobias Nespital; Gerco C Hassink; Jan A Mol
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-18       Impact factor: 5.555

Review 10.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.